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Many biobanks were established as biorepositories for biomedical research, and a number of biobanks were founded in the 
1990s. The main aim of the biobank is to store and to maintain biomaterials for studying chronic disease, identifying risk 
factors of specific diseases, and applying personalized drug therapies. This report provides a review of biobanks, including 
Korean biobanks and an analysis of sample volumes, regulations, policies, and ethical issues of the biobank. Until now, the 
top 6 countries according to the number of large-scale biobanks are the United Kingdom, United States, Sweden, France, the 
Netherlands, and Italy, and there is one major National Biobank of Korea (NBK) and 17 regional biobanks in Korea. Many 
countries have regulations and guidelines for the biobanks, and the importance of good management of biobanks is 
increasing. Meanwhile, according to a first survey of 456 biobank managers in the United States, biobankers are concerned 
with the underuse of the samples in their repositories, which need to be advertised for researchers. Korea Biobank Network 
(KBN) project phase II (2013‒2015) was also planned for the promotion to use biospecimens in the KBN. The KBN is 
continuously introducing for researchers to use biospecimens in the biobank. An accreditation process can also be 
introduced for biobanks to harmonize collections and encourage use of biospecimens in the biobanks. KBN is preparing an 
on-line application system for the distribution of biospecimens and a biobank accreditation program and is trying to 
harmonize the biobanks.
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Introduction
Biobanks provide important materials for many research 
realms, such as biomarker development for the early diag-
noses of specific diseases, including cancer and genetic 
diseases, and for applying personalized drug therapies. 
There is no consensus definition for a biobank, but it is 
considered a biorepository that stores biospecimens for use 
for diagnostic or research purposes. Also, a biobank is an 
institution that collects, stores, processes, and uses biolo-
gical materials, genetic data, and associated epidemiological 
data from human beings or distributes them to researchers 
[1]. The term “research biobank” means a collection of 
human biological material and data obtained directly by the 
analysis of this material, which is used or is to be used for 
research purposes [2]. A repository is defined as an organi-
zation, place, room, or physical entity that may receive, 
process, store, maintain, and/or distribute specimens, their 
derivatives, and their associated data. In this paper, we 
provide a review of biobanks, including Korean biobanks and 
an analysis of sample volumes, regulations, policies, and 
ethical issues of the biobank.
Biobanks around the World
The oldest biobank for the Framingham Heart Study 
(FHS), funded by the National Institute of Health-National 
Heart, Lung, and Blood Institute (NIH-NHLBI), collects 
blood samples and data and was established in 1948. The 
purpose of the Framingham program was the development 
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Name of Biobank Size (age group) Type of biobank Year of start
UK Biobank 500,000 (40‒69 y) P-B & D-O biobank 2006
Estonian Genome Project ~1 million P-B biobank 2001
Icelandic deCode Biobank ~250,000 P-B biobank 1996
Kadoorie Study of Chronic Diseases in China 500,000 (35‒74 y) P-B biobank 2004
Biobank Japan 300,000 D-O biobank 2002
Korea Biobank Project 500,000 P-B & D-O biobank 2008
P-B, population-based; D-O, disease-oriented.
Source: GBI Research, P3G data, KBN website, Biobank Japan website.
Table 1. Biobanks with sample sizes ≥ 200,000 (2012)
of case-finding procedures. A total of 5,209 persons between 
the age of 30 and 62 from Framingham, Massachusetts 
participated in this study, and three generations of parti-
cipants (for a total of almost 15,000 participants) were 
recruited; the researchers began clinical examinations and 
lifestyle-related interviews to seek risk factors related to 
cardiovascular disease (CVD) development. FHS has revea-
led the significant identification of the main CVD risk 
factors, such as high blood pressure, high blood cholesterol, 
smoking, and obesity, as well as immense information on 
factors, such as blood triglyceride and high-density lipo-
protein cholesterol levels, age, and so on [3].    
By the late 1990s, scientists realized that some diseases 
originated from a single defective gene, but most genetic 
diseases are caused by multiple genetic factors on multiple 
genes [4]. For an understanding of whole-genome infor-
mation of humans, the Human Genome Project (HGP) was 
begun in 1990, and the human genome was completely 
released in 2003. 
Owing to the increased demands on qualified biospe-
cimens for research, the number of biobanks has increased 
significantly between 1980 and 1999 worldwide [5]. Many 
countries, including the European countries, Japan, and 
Korea, have established large-scale biobanks to collect a 
large quantity of patient specimens from over 200,000 peo-
ple, based on their population and/or on their disease- 
oriented groups (Table 1). Until now, the top 6 countries, 
according to the number of large-scale biobanks, have been 
the United Kingdom (n = 15), United States (n = 14), 
Sweden (n = 12), France (n = 9), the Netherlands (n = 8), 
and Italy (n = 8). Seventy percent of the world’s biobanks are 
located in Europe. Sixty percent of sponsors for biobanks are 
governmental or national institutes, and 16% to 17% of 
biobanks are sponsored by non-profit public service corpo-
rations, universities, and hospitals. The number of biobanks 
is increasing recently, and particularly, 43 biobanks were 
launched in the 2000s. Most biobanks (60%) recruited less 
than 100,000 people and thirty percents of the biobanks 
recruited 100,000 to 1,000,000 people. The number of 
biobanks collecting blood is 35; 35 collect other biofluids, 43 
collect biomaterials, and 16 secure tissue [6]. 
In 2005, the UK Biobank started collecting DNA samples 
and personal information from 500,000 volunteers aged 
between 45 and 69 years. The main purpose of the UK 
Biobank is to look for the relationship between disease, 
lifestyle, and genes, as well as to identify risk factors that 
affect individual response to specific drug treatment. The UK 
Biobank has collected biospecimens from 500,000 people 
between 2006 and 2010, and they provided their specimens 
to researchers starting from March 2012 [7, 8]. In 2008, 
United States researchers stored 270 million specimens in 
biobanks, and the rate of new sample collection is 20 million 
per year [9]. In 2009, Time magazine chose biobanking as 
one of the 10 ideas “changing the world right now” [10]. 
Elger and Caplan [11] demonstrated that the challenge 
produced by biobanks is immense: after more than 50 years 
of classical health research ethics, regulatory agencies have 
begun to question fundamental ethical milestones. 
A new report by Visiongain (http://www.visiongain. 
com), a business information provider based in London, UK, 
predicts the world market for biobanking on human 
medicine will generate $24.4 bn in 2017 and expand strongly 
to 2023.
In 1995, the Ministry of Education and Science Tech-
nology established the Korea National Research Resource 
Centers for collecting various bioresources. However, the 
scale and variety of the collections were lacking, because 
collections were based on an individual research project. The 
Ministry of Environment established biobanks, but their 
samples were limited to specimens needed for the research 
of environmentally induced diseases. Therefore, there was a 
necessity to establish a biobank that was centered on 
hospitals for collecting human biospecimens [12]. 
In 2008, the Ministry of Health and Welfare started the 
Korea Biobank Project (KBP) and tried to support esta-
blishing biobanks within university-affiliated general hos-
pitals as well as creating a network among these biobanks, 
including National Biobank of Korea (NBK), which is the 
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largest national biorepository in Korea, located in Osong, the 
central region in South Korea [13, 14]. NBK provides 
essential biospecimens to scientific researchers by collec-
ting, maintaining, and distributing DNA and serum, plasma, 
and lymphoblastoid cell line (LCL). 
A new building for NBK, the largest in Asia, was con-
structed in April, 2012 at Osong, Chungcheongbuk-do, 
Korea. The three-story building, including storage rooms 
that can contain 26 million vials of biospecimens, was con-
structed. The structure also has laboratories, an auditorium, 
and so on. The budget for the project was secured from the 
Korean central government in 2008, and the construction 
was started in 2010 and finished in 2012 [14]. Over the 
years, many biobanks, including 17 regional biobanks, have 
been established and are moving from a phase of sample 
collection to open their samples for researches. 
Guidelines for Management and Quality 
Assurance of Biobanks
There are many guidelines for the management of 
biobanks, such as the International Society for Biological and 
Environmental Repositories (ISBER) guideline and Organi-
zation for Economic Cooperation and Development (OECD) 
[15] guideline [16]. ISBER is the largest international forum 
that addresses the technical, legal, ethical, and managerial 
issues relevant to repositories of biological and environ-
mental specimens. ISBER has the “Best Practices for Re-
positories/Collection, Storage and Retrieval of Human 
Biological Materials for Research.” Also, ISBER has intro-
duced standard PREanalytical Coding (SPREC) and can be 
used in the biobank [17]. In October 2009, the OECD 
council adapted a recommendation for Human Biobanks and 
Genetic Research Databases (HBGRDs). The purpose of this 
recommendation suggests guidelines for the establishment, 
management, governance, operation, access, use, and dis-
continuation of HBGRDs, which are structured resources 
that can be used for the purpose of genetic research. The 
OECD Best Practice Guidelines for Biological Resource 
Centers set out further complementary quality assurance 
and technical aspects for the acquisition, maintenance, and 
provision of high-quality biological materials in a secure 
manner. 
The standard operating protocols (SOPs), regulations, 
and management for human biospecimens are important. 
DNA stability and DNA purity in clinical samples are 
essential for correct performance and interpretation for 
diagnosis and research. Generally, quality assurance of hu-
man biospecimens consists of a DNA stability test, DNA 
purity test, microorganism contamination test, and cross- 
contamination test. All biospecimens collected from the 
Korea Genome and Epidemiology Study (KoGES) in the case 
of the NBK underwent a DNA degradation test and purity 
test. Ten percent of biospecimens stored in NBK were 
randomly chosen and tested for the quality assurance test to 
ensure the high quality of DNA extracted from the bio-
specimens and to check contamination by microorganisms. 
The quality of DNA is important for genetic research, such as 
genome-wide association studies (GWASs) and whole- 
genome sequencing (WGS). In general, pure preparations of 
DNA and RNA have an OD260/OD280 of 1.8 and 2.0 
respectively. LCL quality assurance was also conducted, and 
10% of the stocked LCL was randomly selected to undergo 
survival rate investigation and cross-contamination test in 
the NBK [13].
Bioethics and Safety in Biobanks
Informed consent is getting a patient to sign a written 
consent form and is the process of communication between 
a patient and a medical doctor. In medical diagnosis and 
treatment, including invasive procedures, a doctor or a 
researcher must give sufficient information to the patient. 
Informed consent can be given based on a clear under-
standing of the process, implications, and consequences of 
an action. The consent process should include sufficient 
explanation about how individual information would be 
handled [18]. The consent process includes the impact of 
research results on the lives of participants, their families, 
and their communities [19]. Explanations should be on 
confidentiality, participants’ rights of withdrawal, and 
specifications [20].
Due to the difficulties of securing specific informed 
consent, broad consent is a more general form of consent in 
which individuals agree to have their biosamples and 
personal information collected and stored in the biobank and 
for future, unspecified research [21]. Further issues have 
been discussed recently, such as privacy, confidentiality and 
data protection, controlling data access, accessibility to 
biospecimens, benefit sharing, commercialization, intel-
lectual property rights, and genetic discrimination [22].
In order to ensure bioethics and bioethical safety in the life 
sciences and biotechnologies, each of the institutions should 
set up its own Institutional Review Board (IRB). When a 
genetic testing or research institution obtains written in-
formed consent from a test subject concerning the use of 
specimens for research purposes, it may provide the 
specimens to either a person conducting research on genes 
or an institution licensed to open a biobank in Korea [1]. 
In Korea, the Bioethics and Safety Act was completely 
revised to reinforce research ethics, including biobanks, and 
the law took effect in 2013. The number of biobanks within 
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Cohort








10,038 (baseline 2001‒2002) 1,922 Open 8,842 O (HapMap) Affy 5.0 Open 
4,690 CGH array chip Open 
  100 Illumina Hiseq Open 
8,603 (1st follow-up 2003‒2004) 1,831 Open - - - -
7,515 (2nd follow-up 2005‒2006) 2,490 Open - - - -
Health Examinee 
Cohort/KoGES
3,703 (subset of baselines 2006‒2007) 255 Open 3,703 O (HapMap) Affy 6.0 Open 
CAVAS CAVAS I 3,667 (subset of baselines 2004‒2008) 249 Open 3,667 O (HapMap) Illumina OMni1 Open 
CAVAS II 1,816 (subset of baselines 2005‒2006) 193 Open 1,816 O (HapMap) Affy 6.0 Open 
Twin Cohort 1,861 (subset of baselines 2005‒2008) 206 Open 1,861 Affy 6.0 Open 
QC, quality control; KoGES, Korea Genome and Epidemiology Study; CAVAS, Cardiovascular Disease Association Study. 
Table 2. Data for distribution ofthe National Biobank of Korea (as of June 2013)
Cohort
Biospecimens
Seruma Plasmaa Urinea DNA LCL LCL-DNA Release
Community-based (Ansung/Ansan)
 Cohort/KoGES
11,756 9,978 11,208 12,010 10,463 10,752 Open to the researchers
CAVAS 64,664 64,631 64,337 54,734 - - Open to the researchers
Health Examinee Cohort/KoGES 128,396 128,519 127,539 119,220 - - Open to the researchers
Twin Cohort 3,088 3,154 3,128 3,240 2,443 498 Open to the researchers
The Korea National Health and Nutrition
 Examination Study (KNHNES)
44,505 27,933 - 25,644 - - Open to the researchers
Total 254,409 236,215 206,212 216,848 12,906 11,205
LCL, lymphoblastoid cell line; KoGES, Korea Genome and Epidemiology Study; CAVAS, Cardiovascular Disease Association Study.
aA part of them is being distributed to the researchers.
Table 3. Biospecimens for distribution of the National Biobank of Korea (as of June 2013)
university-affiliated hospitals will increase. This law en-
courages biobanks to strengthen ethical use of biospeci-
mens, and the law assesses biobanks’ responsibility to ob-
tain informed consent from donors and is supervised by the 
IRB. The law also encourages individual researchers to de-
posit and use biospecimens at any biobank instead of 
collecting their own sample collection and distribution 
processes [1, 14]. 
Distribution Policy for Biospecimens and 
Data 
Many biobanks have policies for the distribution of 
biospecimens and data. For example, there is a guideline to 
distribute biospecimens in the National Health and Nu-
trition Examination Survey (NHANES), which is a program 
of studies designed to assess the health and nutritional 
status of adults and children in the United States. NHANES’s 
biospecimens are representative samples of Americans and 
should not be used for the independent case-control study, 
and 1individual vial must be stored permanently. All 
proposals for the use of NHANES samples are evaluated by 
a technical panel for scientific merit and by the NHANES 
Ethics Review Board (ERB). To determine if this limited 
resource should be used in the proposed projects, a technical 
panel will evaluate the public health significance and scien-
tific merit of the proposed research. Distribution of a 0.5-mL 
sample is available once, and after finishing the research, the 
remaining samples are abandoned, or remnants more than 
0.3 mL should be returned to NHANES; third-party bio-
specimen transfer is not permitted. Researchers who re-
ceived specimens must submit the result of the analysis, 
such as quality control and analytical methods with docu-
ments, to the National Center for Health Statistics (NCHS). 
Surplus data without DNA analysis results would be opened 
in the website and given a period of 3 months for analysis. A 
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researcher’s intellectual property rights are not permitted 
because of research for public health (http://www/cdc/ 
gov/nchs/nhanes.htm). 
The Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial (PLCO) biorepository in the United States 
has 2.9 million biological samples, including blood, and 
researchers can use samples and data through the process of 
peer review. Researchers can submit summarized proposals 
to the PLCO, and the chosen research is recommended for 
full research proposals and submissions are available twice 
in June/July or December/January annually. The review 
process takes 4 or 6 months. Researchers with approved 
proposals should submit IRB approval documents and 
contract the Material Transfer Agreement (MTA) mutually, 
and biospecimens are distributed to researchers when ap-
proved; researchers should report experimental results to 
Information Management Systems (IMS) (http://www. 
plcostars.com).
At present, distribution of biospecimens is available to 
Korean researchers irrespective of research funds, and the 
distribution for data is accessible to Korean researchers 
without financial sponsors in Korean biobanks. All pro-
posals for distribution of data and biospecimens should be 
reviewed and be approved by the IRB belonging to an 
institute prior to submission. Opened data and biospe-
cimens for distribution in the NBK are shown in Tables 2 and 
3. First of all, researchers who want to receive the data and 
biospecimens have to submit the application document to 
the NBK. The submitted documents will be reviewed, and a 
board meeting for distribution is held monthly; distribution 
of work for the approved application will be performed 
approximately within one or two months from submission 
of the application documents for distribution. NBK is 
planning a website for the distribution process. 
Most of the distributed biospecimens are DNA samples in 
the NBK, and a few body fluid samples, including sera and 
plasma, were distributed. According to the advancement of 
the technology, the minimum quantity for clinical exami-
nation and for the analysis of metabolites is diminishing. 
However, sera and plasma are very limited resources, and 
political decisions and long-term planning for the use of 
body fluid samples will be needed [12]. 
Studies Using Biospecimens of Biobanks 
In 2000, following the HGP, biological research moved 
into the so-called genomic era. Diseases have been studied 
by identifying genes and their specific function and under-
standing the role played by genetics in the beginning and 
prognosis of diseases, and an advanced world of medicine, 
known as “personalized medicine,” has been initiated [5].
Accessibility to human specimens and data for the pur-
poses of research is important for realms, such as genomics, 
proteomics, metabolomics, molecular imaging, and nano-
technology [23]. There are genetic factors that affect sus-
ceptibility to common diseases [24]. These diseases may 
have several genetic risk factors that influence each other, 
and interact with the environment, and this has spurred the 
development of large-scale biobanking projects to identify 
susceptible genes [25].
Despite intensive research over the last decade, most of 
the genetic basis of common human diseases remains un-
known. The identification of meaningful genetic variants, 
genes, and pathways involved in special diseases offers a 
potential route to new therapies, improved diagnosis, and 
better disease prevention. For some time, it has been hoped 
that the advent of GWASs would provide a successful new 
tool for solving the genetic basis of many of these common 
causes of human morbidity and mortality.
Advances in sequencing technology enabled us to se-
quence the whole human genome [26, 27]. The use of WGS 
of large patient cohorts is a much-needed approach in 
researching complex traits; it is still being ruled out to detect 
low-frequency genetic variants, due to its high costs [28, 29].
Among the new and emerging fields of research is 
proteomics, the study of the full set of proteins encoded by 
the genome. Also, proteomics is strongly associated with the 
discovery phase, the first step in the process chain to create 
diagnostic content [30]. 
Future Plans for Biobanks, Including the 
Korea Biobank Network (KBN)
Due to the increased demands on qualified biospecimens 
for research, the number of biobanks has significantly in-
creased recently. By virtue of the advancements in bio-
informatics and biotechnology, storing biospecimens and 
data on a large scale requires that biobanks harmonize 
biobank processes and regulations [5]. 
Most biobanks did their best to secure more biospecimens 
at the inception of the foundation and comparably distri-
bution rate for the researchers is low. According to a first 
survey of 456 biobank managers in the United States, nearly 
70% of those questioned were concerned with underuse of 
the samples in their repositories [31]. Therefore, many 
biobankers are trying to advertise their biospecimens to 
researchers in regional academic societies. Like the United 
States, the NBK has faced a similar situation for the 
underuse of biospecimens stored in the biobank. In the first 
phase of the KBP (2008‒2012), biobanks concentrated on 
securing facilities, such as storage equipment, as well as 
securing manpower and funding for biobanks. However, in 
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the second phase (2013‒2015), more R&D projects are 
needed that support clinicians, so that it will be possible to 
gather resources with more information.
For maximizing the value of biospecimens, consistency in 
the methods by which they are retrieved, processed, stored, 
and transported is important. Ideally, this should involve the 
use of agreed SOPs in general [32]. The other issue in the 
next big step is automated biobanking, and today’s biobanks 
demand and move toward automated sample management 
systems that meet the requirements for reliability, sample 
integrity, high capacity, and high throughput.
Horn, the former director of the Genetic Alliance, demon-
strates that biobanks have to cooperate together to achieve 
their mission, and standardization is going to be important 
for researchers to get samples from different collections; we 
need catalogs that say where these samples exist [33]. Ac-
creditation processes can also be introduced to biobanks for 
harmonizing collections and encouraging use of biospe-
cimens in the biobanks, including the KBN. The NBK is also 
preparing an online distribution portal for the convenient 
application of distribution to researchers and preparing a 
biobank accreditation program; these will harmonize the 
biobanks in Korea. 
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